Phosphodiesterase (PDE) Inhibitors Market 2024-2028
The global phosphodiesterase (PDE) inhibitors market size is estimated to grow by USD 3.78 billion at a CAGR of 6.85% between 2023 and 2028.
The phosphodiesterase (PDE) inhibitors market has witnessed the advent of new-generation PDE inhibitors in the past few years. In addition to PDE4 and PDE5 inhibitor approvals, the global phosphodiesterase (PDE) inhibitors market has also witnessed the approvals of other PDE inhibitors over the past few years, which is fueling the market growth. In January 2021, Merck announced that the VERQUVO had been approved by the Food and Drug Administration (FDA). It is a soluble guanylate cyclase (sGC) stimulator used to lower the risk of cardiovascular death and heart failure hospitalization. Therefore, such efforts by players to launch new PDE inhibitors in the market and expand the therapeutic applications of the existing PDE inhibitors are anticipated to increase the demand and adoption of PDE inhibitors for the treatment of various diseases, thereby driving market growth during the forecast period.
Technavio has segmented the market into Application, Type, and Geography
- The application segment includes oral, topical, and other RoA
- The type segment includes PDE5 inhibitors, PDE4 inhibitors, and PDE3 and others
- The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)
It also includes an in-depth analysis of drivers, trends, and challenges. Besides analyzing the current market scenario, our report examines historical data from 2018 - 2022.
What will be the size of the Phosphodiesterase (PDE) Inhibitors Market During the Forecast Period?
_inhibitors_market_size_abstract_2024_v1.jpg)
To learn more about this report, Download Report Sample
Phosphodiesterase (PDE) Inhibitors Market Segmentation by Application, Type, and Geography Analysis
Application Analysis
Oral
The market share growth by the oral segment will be significant during the forecast period. Considering the high therapeutic efficacy of PDE5 inhibitors for the treatment of ED in men, these drugs have gained significant importance over the past few years. PDE5 inhibitors are a class of drugs that block the action of phosphodiesterase type 5 (PDE5) enzyme. Some of the major market players are offering oral PDE5 inhibitors, which are being extensively used for the treatment of ED and are among the major revenue contributors to the market.
_inhibitors_market_segments_abstract_2024_v2.jpg)
Get a glance at the market contribution of various segments Download PDF Sample
The oral segment was valued at USD 5.73 billion in 2018. PDE5 inhibitors are also formulated as sublingual dosage forms. In addition to PDE5 inhibitors, other PDE inhibitors are being extensively used in this dosage form. OTEZLA (apremilast) by Celgene Corp. (Celgene) is an orally administered PDE4 inhibitor used for the treatment of psoriatic arthritis. It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. Moreover, the rising prevalence of various chronic diseases will ensure continuous adoption of oral PDE inhibitors for their treatment, which would drive the growth of the segment and market during the forecast period.
Type Analysis
PDE5 inhibitors
PDE5 inhibitors commonly include sildenafil, tadalafil, vardenafil, and avanafil. PDE5 inhibitors are a group of drugs most generally used to treat erectile dysfunction (ED). ED is the most common disease found in older men. The global prevalence of erectile dysfunction is projected to grow to 322 million men by 2025. The growing prevalence and demand for efficient treatment of ED are encouraging vendors to introduce effective products. For instance, in June 2023, Futura Medical received FDA approval for its Eroxon, an OTC topical gel for ED. Therefore, the growth of PDE5 inhibitors in the global phosphodiesterase inhibitors market is expected to propel during the forecast period.
PDE4 inhibitors
PDE4 inhibitors work by suppressing the immune system, thereby reducing inflammation. Systemically delivered PDE4 inhibitors have been limited by systemic adverse reactions. Inhaled PDE4 inhibitors may be an option to improve tolerability and determine the maximal therapeutic potential of PDE4 inhibition in the respiratory system. Increasing autoimmune diseases is promoting vendors in the field to launch new products in respective segments. Thus, such factors are expected to boost the growth of the segment in the phosphodiesterase inhibitors market during the forecast period.
Regional Analysis
_inhibitors_market_regions_abstract_2023_geo_v2.jpg)
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have explained the regional trends and drivers that will shape the market during the forecast period. North America is the largest region due to large pharmaceutical companies offering both branded and generic PDE inhibitors and a proper regulatory framework for the approval of new drugs in the region. Phosphodiesterase (PDE5) inhibitors are most commonly used to treat ED. ED is widely regarded as the most common form of sexual dysfunction in men, and it becomes more prevalent as men age. It is estimated that anywhere between 30 million to 50 million men in the US deal with ED.
Moreover, the increased disposable income of people is leading to a large number of patients opting for the PDE inhibitors treatment, thereby contributing to the market growth in this region. In addition, the increased focus of key market players on investing in R&D activities to maintain their market position is anticipated to have a positive impact on phosphodiesterase inhibitors market growth during the forecast period.
Key Phosphodiesterase (PDE) Inhibitors Market Players
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Amgen Inc.: The company offers phosphodiesterase inhibitor namely OTEZLA.
- AbbVie Inc.
- AstraZeneca Plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Deciphera Pharmaceuticals Inc
- Dong A Socio Holdings Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- United Therapeutics Corp.
- Viatris Inc.
- VIVUS LLC
- Zydus Lifesciences Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Phosphodiesterase (PDE) Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Key Phosphodiesterase (PDE) Inhibitors Market Drivers
The rising prevalence of ED is the key factor driving market growth. ED is a medical condition characterized by the inability to achieve erection enough for satisfactory sexual intercourse. The etiology of ED can be attributed to multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia. In addition, the consumption of certain medicines and substance abuse can lead to ED. As most of these factors are related to lifestyle changes, the prevalence of ED is increasing globally.
Furthermore, the corpus cavernosum smooth muscle contraction is defined as the inability of muscles to relax, which can subsequently lead to ED. Considering rapid urbanization, lifestyle changes, including increased tobacco use and alcohol consumption, and high employment stress, young men are more susceptible to ED. The increase in the incidence of ED is expected to boost the adoption of PDE5 inhibitors during the forecast period. Thus, it is expected to propel the growth of the market during the forecast period.
Significant Phosphodiesterase (PDE) Inhibitors Market Trends
The application of new technologies for PDE inhibitor development is the primary trend shaping market growth. PDE enzymes are of 11 types; of these, PDE5 has gained significant attention over the years after its recognition as the major target enzyme for treating ED. PDE5 enzymes have an amino acid sequence and molecular structure similar to PDE6 and PDE11, and hence, first-generation PDE5 inhibitors, such as sildenafil and vardenafil, are also competitive inhibitors of PDE6 and PDE11. Thus, the application of novel technologies for the development of PDE5 inhibitors, which can decrease their cross-reactivity with PDE6 and PDE11 enzymes, is required. For this purpose, a similarity-based virtual screening technique, such as the ZINC database, is used.
In addition, ZINC is a free public resource database that contains more than 20 million small molecular compounds. The database enables researchers to access the chemoinformatics and biological activities of small molecules to aid in drug development and strengthen the understanding of minute differences between two compounds sharing similar molecular structures through virtual screening. Thus, such initiatives are likely to propel the growth of the global phosphodiesterase (PDE) inhibitors market during the forecast period.
Major Phosphodiesterase (PDE) Inhibitors Market Challenges
Increasing the launch of generics is a challenge that affects market growth. In September 2018, Teva launched the generic version of CIALIS (tadalafil) in the US, which is used for the treatment of ED. Following the launch of generic sildenafil and tadalafil, the sales of their branded versions, VIAGRA from Pfizer and CIALIS from Eli Lilly, decreased significantly. For example, in September 2020, research was conducted in which patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 inhibitors to riociguat experienced clinical improvement at 24 weeks.
Furthermore, following the loss of patent exclusivity, the generic competition for a product increases, leading to a decrease in the product sales of branded drugs as the generic competitor enters the market with the same product at lower prices. This also increases the threat of new entrants in the market, which, in turn, disrupts the market position of the existing players. Thus, such factors are anticipated to the market growth during the forecast period.
Key Phosphodiesterase (PDE) Inhibitors Market Customer Landscape
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
_inhibitors_market_customer_landscape_abstract_2023_geo_v1.jpg)
Global Phosphodiesterase (PDE) Inhibitors Market Customer Landscape
Segment Overview
The phosphodiesterase (PDE) inhibitors market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.
- Application Outlook
- Oral
- Topical
- Other RoA
- Type Outlook
- PDE5 inhibitors
- PDE4 inhibitors
- PDE3 and others
- Region Outlook
- North America
- The U.S.
- Canada
- Europe
- The U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- Rest of World (ROW)
- Argentina
- Australia
- Brazil
- North America
|
Phosphodiesterase (PDE) Inhibitors Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
165 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.85% |
|
Market Growth 2024-2028 |
USD 3.78 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
6.15 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, Germany, UK, France, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Deciphera Pharmaceuticals Inc, Dong A Socio Holdings Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., Viatris Inc., VIVUS LLC, and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
What are the Key Data Covered in this Phosphodiesterase (PDE) Inhibitors Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the phosphodiesterase (PDE) inhibitors market between 2024 and 2028
- Precise estimation of the phosphodiesterase (PDE) inhibitors market size and its contribution to the market in focus on the parent market
- Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
- Companies landscape comparing criticality of inputs and factors of differentiation
- Exclusive Matrix on companies' position and classification
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of phosphodiesterase (PDE) inhibitors market companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch